Clinical Trial Update: Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating DTPw-HBV/Hib at 15-18 months followed by Mencevax ACWY at 24-30 months in primed subjects; the study is completed and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis Meningococcal
• Meningococcal Disease

Drugs mentioned

• DTPw-HBV/Hib vaccine (Diphtheria and Tetanus Toxoids and Whole-Cell Pertussis vaccine, with Hepatitis B and Haemophilus influenzae type b)
• Mencevax ACWY vaccine (Mencevax ACWY vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-03-01